In patients with localized bladder cancer who were treated with preoperative ipilimumab, CD4+ T cells from the peripheral blood and tumor tissues were found to have increased expression of ICOS (inducible costimulator) compared to patients who did not receive ipilimumab. Here, ICOS is linked to neoplasm.